Eukaryotic transcription activators stimulate the expression of specific sets of target genes through recruitment of co-activators such as the RNA polymerase II-interacting Mediator complex^[@R1],[@R2]^. Aberrant function of transcription activators has been implicated in a number of diseases. However, therapeutic targeting efforts have been hampered by a lack of detailed molecular knowledge of the mechanisms of gene activation by disease-associated transcription activators. We previously identified an activator-targeted three-helix bundle KIX domain in the human MED15 Mediator subunit that is structurally conserved in Gal11/Med15 Mediator subunits in fungi^[@R3],[@R4]^. The Gal11/Med15 KIX domain engages pleiotropic drug resistance transcription factor (Pdr1) orthologues, which are key regulators of the multidrug resistance (MDR) pathway in *S. cerevisiae* and in the clinically important human pathogen *Candida glabrata*^[@R5],[@R6]^. The prevalence of *C. glabrata* is rising, partly due to their low intrinsic susceptibility to azoles, the most widely used antifungal^[@R7],[@R8]^. Drug-resistant clinical isolates of *C. glabrata* most commonly harbour point mutations in Pdr1 that render it constitutively active^[@R9]--[@R14]^ suggesting that this transcriptional activation pathway represents a linchpin in *C. glabrata* MDR. We have carried out sequential biochemical and *in vivo* high-throughput screens to identify small molecule inhibitors of the interaction of the *C. glabrata* Pdr1 activation domain with the *C. glabrata* Gal11A KIX domain. The lead compound (*iKIX1*) inhibits Pdr1-dependent gene activation and re-sensitizes drug-resistant *C. glabrata* to azole antifungals *in vitro* and in animal models for disseminated and urinary tract *C. glabrata* infection. Determining the NMR structure of the *C. glabrata* Gal11A KIX domain provided a detailed understanding of the molecular mechanism of Pdr1 gene activation and MDR inhibition by *iKIX1*. We have demonstrated the feasibility of small molecule targeting of a transcription factor-binding site in Mediator as a novel therapeutic strategy in fungal infectious disease. Based on our previous findings that deletion of the KIX domain of *Saccharomyces cerevisiae GAL11* or *Candida glabrata GAL11A* abrogates Pdr1-dependent transcriptional responses and xenobiotic tolerance we hypothesized that the *Cg*Pdr1-*Cg*Gal11A interaction interface might serve as a promising target for novel anti-MDR compounds^[@R3]^. A fluorescently tagged *Cg*Pdr1 activation domain (AD) was used in an *in vitro* fluorescence polarization (FP) screen^[@R15]^ of \~140,000 chemically diverse compounds to identify small molecules that block the interaction between the *Cg*Gal11A KIX domain and the *Cg*Pdr1 AD ([Extended Data Fig. 1](#F5){ref-type="fig"}). Based on the high degree of conservation between *S. cerevisiae* and *C. glabrata*, we followed up the top hits from the FP screen with an azole growth inhibition screen in *S. cerevisiae* to identify hits with *in vivo* efficacy ([Fig. 1*a*](#F1){ref-type="fig"}). We identified 5 compounds that reproducibly inhibited growth in a concentration-dependent manner only in the presence of ketoconazole ([Extended Data Fig. 1](#F5){ref-type="fig"}). The most potent compound is referred to as *iKIX1* ([Fig. 1*b, c*](#F1){ref-type="fig"}). *In vitro* binding studies revealed that the Kd of the *Cg*Pdr1 AD for the *Cg*Gal11A KIX domain is 0.32 µM and the apparent Ki for *iKIX1* is 18 µM ([Fig. 1*d*](#F1){ref-type="fig"}).

To facilitate the elucidation of the mechanism of action of *iKIX1*, we determined the high-resolution solution structure of the *Cg*Gal11A KIX domain with a backbone RMSD of 0.7 Å ([Fig. 2](#F2){ref-type="fig"} and [Extended Data Table 1](#T1){ref-type="table"}; PDB \# *4D7X*). The *Cg*Gal11A KIX domain has 51% sequence identity and 61% similarity with the *S. cerevisiae* Gal11/Med15 KIX domain^[@R3]^ with an overall RMS deviation of 2.0 Å ([Fig. 2*a*](#F2){ref-type="fig"} & [Extended Data Fig. 2*c*](#F6){ref-type="fig"}). The *Cg*Gal11A KIX domain forms a three-helix bundle harbouring an extensively hydrophobic core and a short helix at the N-terminus ([Fig. 2*a*](#F2){ref-type="fig"}). We determined interaction interfaces of the *Cg*Gal11A KIX domain with the *Cg*Pdr1 AD and *iKIX1* ([Fig. 2*b*](#F2){ref-type="fig"}) by chemical shift perturbation (CSP) analysis. The *Cg*Pdr1 AD and *iKIX1* target the same large hydrophobic groove harboured by the three helices. Residues from all three helices constitute the interaction interface, and titration of an ILV-methyl labeled *Cg*Gal11A KIX domain reveals large CSPs on the three leucines (L19, L23 and L51) upon addition of *Cg*Pdr1 AD and *iKIX1* ([Extended Data Fig. 2*b*](#F6){ref-type="fig"}). The basic interaction interface on the KIX domain complements the acidic residues of *Cg*Pdr1 AD ([Fig. 2*c*](#F2){ref-type="fig"}). Residues of the *Cg*Gal11A KIX domain that interact with *Cg*Pdr1 AD and *iKIX1* overlap strongly, suggesting direct competitive binding as the mechanism of inhibition. Docking of *iKIX1* to the *Cg*Gal11A KIX domain suggests extensive hydrogen bonding and hydrophobic interactions between *iKIX1* and KIX domain residues ([Fig. 2*d*](#F2){ref-type="fig"} and [Extended Data Fig. 2*a*](#F6){ref-type="fig"}), matching the interaction interface mapped by CSP analysis.

To assess the *in vivo* effects of *iKIX1* on Pdr1-dependent transcription, we initially utilized a strain in which the two *S. cerevisiae PDR1* orthologues (*ScPDR1* and *ScPDR3*) are deleted and which carries a plasmid expressing *CgPDR1*^[@R3]^, and a heterologous luciferase gene driven by 3 pleiotropic drug response elements (PDREs). Luciferase activity was strongly induced by ketoconazole treatment; *iKIX1* co-treatment was able to block this induction in a concentration-dependent manner ([Fig. 3*a*](#F3){ref-type="fig"}).

A chromatin immunoprecipitation (ChIP) assay was used to examine Gal11/Med15 recruitment to Pdr1-regulated target genes in *S. cerevisiae* after *iKIX1* treatment. Gal11/Med15 was rapidly recruited to the promoters of the Pdr1 target genes *PDR5* and *SNQ2* after ketoconazole addition; in contrast, ketoconazole-induced recruitment of Gal11/Med15 was abrogated when the cells were pre-treated with *iKIX1* ([Fig. 3*b*](#F3){ref-type="fig"}, [Extended Data Fig. 3*a*](#F7){ref-type="fig"}). *iKIX1* did not impede the constitutive occupancy of Pdr1 at the same Pdr1-regulated target genes ([Extended Data Fig. 3*b*](#F7){ref-type="fig"}). Consistent with the ChIP data, *iKIX1* strongly inhibited azole-induced transcription of *Sc*Pdr1 target genes ([Fig. 3*c*](#F3){ref-type="fig"}, [Extended Data Fig. 3*a, c*](#F7){ref-type="fig"}).

Next, we determined the effect of *iKIX1* on the transcription of *C. glabrata* Pdr1-regulated genes involved in drug efflux and MDR (*CgCDR1, CgCDR2* and *CgYOR1*). *Cg*Pdr1 targets were strongly up-regulated after ketoconazole treatment^[@R12],[@R16]^. However, pre-treatment with *iKIX1* reduced target gene induction in a durable and concentration-dependent manner ([Fig. 3*d*](#F3){ref-type="fig"} and [Extended Data Fig. 4*a, b*](#F8){ref-type="fig"}). Treatment with *iKIX1* alone did not significantly affect Pdr1-target gene induction ([Extended Data Fig. 4*c, d*](#F8){ref-type="fig"}).

Next generation RNA sequencing (RNA-Seq) was employed to query the genome-wide effects of *iKIX1* and azole treatments alone and in combination on the transcriptome in both *S. cerevisiae* and in *C. glabrata*. In accord with previous reports^[@R16],[@R17]^, azole treatment up-regulates Pdr1-dependent genes in both yeasts, such as the drug efflux pumps *ScPDR5* and *CgCDR1* ([Supplementary Tables 1 and 2](#SD5){ref-type="supplementary-material"}). Combined azole and *iKIX1* treatment strongly blunted expression of many azole-activated and Pdr1-dependent genes in both *S. cerevisiae* and *C. glabrata* ([Fig. 3*e*](#F3){ref-type="fig"}, [Extended Data Fig. 3*d*](#F7){ref-type="fig"} and [Supplementary Tables 1 and 2](#SD5){ref-type="supplementary-material"}), consistent with prior data and the proposed mechanism of action of *iKIX1*. *iKIX1* alone affected very different sets of genes in *S. cerevisiae* and *C. glabrata* ([Supplementary Tables 1--3](#SD5){ref-type="supplementary-material"}). Treatment of *S. cerevisiae* and *C. glabrata* cells with *iKIX1* did not significantly alter the expression of *PDR1* or *GAL11/MED15* after azole treatment ([Extended Data Fig. 3*e*](#F7){ref-type="fig"}). Together, these findings suggest that the primary mechanism of synergistic antifungal effects of *iKIX1* with azoles is through blocking the azole-stimulated and Pdr1-dependent drug efflux pathway.

To ascertain *iKIX1* efficacy in azole-resistant *C. glabrata* strains, we examined the effects of *iKIX1* on *Cg*Pdr1 target gene expression in a set of isogenic strains with gain-of-function *CgPDR1* mutations originally identified in azole-resistant *C. glabrata* clinical isolates^[@R9]^. *iKIX1* reduced azole-induced transcription of *Cg*Pdr1 target genes (e.g., *CgCDR1*) in a concentration-dependent manner in all strains tested ([Fig. 3*f*](#F3){ref-type="fig"} and [Extended Data Fig. 4*d*](#F8){ref-type="fig"}).

To investigate whether these transcriptional effects translated to functional effects on drug efflux rates, we utilized the fluorescent compound rhodamine 6G, a substrate of the *Cg*Cdr1 efflux pump^[@R18],[@R19]^. Maximum efflux rates were significantly decreased in *PDR1* wild-type or gain-of-function strains pre-treated with *iKIX1*, as compared to vehicle control ([Fig. 3*g*](#F3){ref-type="fig"} and [Extended Data Fig. 5](#F9){ref-type="fig"}).

Due to its ability to reduce efflux pump gene expression and pump activity, we predicted that *iKIX1* could restore azole-sensitivity to *CgPDR1* gain-of-function mutant strains. Isogenic *C. glabrata* strains with wild-type or single gain-of-function alterations across *Cg*Pdr1 ([Fig. 4*a*](#F4){ref-type="fig"}) were tested for their sensitivity to fluconazole or ketoconazole on gradient plates with increasing concentrations of *iKIX1* or vehicle. As expected, a *CgPDR1* wild-type strain was sensitive to both fluconazole and ketoconazole, whereas *CgPDR1* gain-of-function mutant strains grew robustly in the presence of azoles. *iKIX1* restored azole-sensitivity to *PDR1* gain-of-function mutant strains in a concentration-dependent manner ([Fig. 4*b*](#F4){ref-type="fig"}). *CgPDR1* wild-type strains also exhibited increased growth inhibition in the presence of both *iKIX1* and azole versus single agents alone ([Extended Data Fig. 6*a, b*](#F10){ref-type="fig"}).

Based on the strong combination effect of azoles and *iKIX1* in the *CgPDR1^L280F^* mutant we focused follow-up studies on this mutant strain. To investigate whether azoles and *iKIX1* act in a synergistic or additive manner in *CgPDR1* wild-type and *CgPDR1^L280F^* mutant strains, we assessed growth in checkerboard assays with ketoconazole and *iKIX1*. In the wild-type *CgPDR1* strain, the combination of ketoconazole and *iKIX1* was additive ([Extended Data Fig. 6*c*](#F10){ref-type="fig"}). However, the *CgPDR1^L280F^* mutant exhibited synergistic growth inhibition with *iKIX1* and ketoconazole combination treatment, with combination indices \<1 ([Extended Data Fig. 6*d*](#F10){ref-type="fig"}), in concordance with the spot-plating assay.

We carried out a limited analysis exploring the chemical space around the *iKIX1* scaffold using commercial and custom synthesized *iKIX1* analogs, identifying several compounds that lost activity in all assays; one analog (A2) is shown in [Extended Data Figure 7*a--d*](#F11){ref-type="fig"}. This example, together with data from *iKIX1* analogs and the docked structure of *iKIX1* to the *Cg*Gal11A KIX domain, supports a model where *iKIX1* engages the core of the KIX domain using an array of hydrophobic and hydrogen bond contacts.

We utilized two metazoan model systems to evaluate the potential utility of *iKIX1* as a co-therapeutic with fluconazole to treat disseminated *C. glabrata* infection. The larvae of the moth *Galleria mellonella* has been used as a model to test the pathogenicity of a wide variety of human pathogens^[@R20]^. We utilized a *G. mellonella* survival assay to determine the virulence of *C. glabrata PDR1* wild-type or *PDR1^L280F^* strains in the presence of fluconazole, *iKIX1*, or a combination of the two ([Fig. 4*c*](#F4){ref-type="fig"}). Larvae were injected with *C. glabrata* and a single injection of fluconazole (50 mg/kg), *iKIX1* (25 mg/kg), a combination of the two, or vehicle; survival was monitored every 24 hours. *G. mellonella* injected with wild-type *CgPDR1* was sensitive to fluconazole alone, and exhibited no significant alterations in survival with a fluconazole-*iKIX1* combination. However, in *G. mellonella* larvae injected with a *CgPDR1^L280F^* strain, whereas the single agents fluconazole or *iKIX1* did not significantly increase survival compared to vehicle, co-treatment with *iKIX1* and fluconazole significantly increased survival (P\<0.001).

Prior to mammalian studies, we sought to evaluate the potential toxicity of *iKIX1* in mammalian cells ([Extended Data Fig. 7*e, f*](#F11){ref-type="fig"}). Human HepG2 cells treated with *iKIX1* revealed toxicity only at high concentrations of *iKIX1* (IC50 \~100 µM). *iKIX1* had no effect on the transcription of SREBP-target genes at concentrations up to 100 µM, indicating its specificity for the fungal Gal11/Med15 KIX domain^[@R4]^. We also assessed the *in vitro* stability and *in vivo* mouse pharmacokinetics of *iKIX1* and found that *iKIX1* exhibited favorable drug-like properties and *in vivo* exposure in these studies ([Extended Data Fig. 8*g,h*](#F12){ref-type="fig"}).

To evaluate the therapeutic potential of *iKIX1* and azole antifungal co-therapy in a mammalian model, we initially turned to an established mouse model of disseminated fungal disease^[@R11]^. Mice were inoculated with *C. glabrata* by tail-vein injection and were dosed peritoneally once-daily with 100 mg/kg fluconazole (high FLU), 100 mg/kg *iKIX1*, a combination of the two, or vehicle alone. After 7 days, mice injected with a *CgPDR1* wild-type strain exhibited significantly reduced tissue fungal burden in the kidney and spleen following fluconazole treatment alone; *iKIX1* co-treatment did not result in further reductions ([Fig. 4*d*](#F4){ref-type="fig"}). In contrast, in mice injected with the azole-resistant *CgPDR1^L280F^* strain, only co-treatment with *iKIX1* and fluconazole resulted in significant (\~10-fold) reductions in fungal burdens in the kidney and spleen (P\<0.0001) ([Fig. 4*d*](#F4){ref-type="fig"}). Similar results were observed with the clinically isolated *CgPDR1^+^* and *CgPDR1^L280F^* strains DSY562 and DSY565 ([Extended Data Fig. 8*a*](#F12){ref-type="fig"}). Consistent with previous studies^[@R9]^, the fungal burden in mice infected with the *CgPDR1^L280F^* strain was higher than those infected with wild-type Cg*PDR1* strains, suggesting that *PDR1* mutant strains may be more virulent *in vivo*. Similar but less pronounced results were found in mice injected with a *CgPDR1^P822L^* strain ([Extended Data Fig. 8*b*](#F12){ref-type="fig"}). When mice were injected with a *CgPDR1* wild-type strain and dosed with 25 mg/kg fluconazole (low FLU) alone or in combination with *iKIX1*, fluconazole alone poorly reduced tissue burden, whereas combination treatment resulted in significant (\~10-fold) reductions in fungal burdens in both organs (P\<0.0001) ([Fig. 4*d*](#F4){ref-type="fig"}). These results suggest that *iKIX1* combination treatment with azole may be therapeutically desirable even in the absence of *CgPDR1* gain-of-function mutations. Mice infected with a *Cgpdr1* null strain were more sensitive to *iKIX1* alone; unlike mice infected with *CgPDR1^+^* or *CgPDR1^L280F^* strains, low doses of *iKIX1* did not further reduce fungal burden in *Cgpdr1 null* infections ([Extended Data Fig. 8c,*d*](#F12){ref-type="fig"}).

*CgPDR1* gain-of-function mutations are also known to control adherence to host cells. As previously observed^[@R21]^, a *PDR1^L280F^* mutant increased relative adherence to epithelial cells as compared to a *PDR1* wild-type strain. Strikingly, *iKIX1* treatment alone reduced adherence to levels similar to a *PDR1* wild-type strain ([Extended Data Fig. 8*e*](#F12){ref-type="fig"}). Ketoconazole alone or co-treatment with *iKIX1* also reduced relative adherence to levels comparable to a *PDR1* wild-type strain. To assess the role of *iKIX1* in modulating adhesion in an infection model, we turned to a mouse model of urinary tract infection^[@R22]^. In both the bladder and kidney, *iKIX1* alone was sufficient to decrease fungal load after infection with either a *PDR1* wild-type strain or a *PDR1^L280F^* strain ([Extended Data Fig. 8*f*](#F12){ref-type="fig"}), suggesting that *iKIX1* may indeed modulate adhesion.

The proportion of azole-resistant *C. glabrata* (up to 20% in the US) and the emergence of multidrug resistance (approximately 40% of echninocandin-resistant isolates are azole-resistant) argues for the need for novel treatments that can target these resistant populations^[@R23],[@R24]^. Our results demonstrate that small molecule disruption of the interaction between the *Cg*Gal11A KIX domain and the *Cg*Pdr1 activation domain is a therapeutically tractable method for resensitizing azole-resistant *C. glabrata* to standard azole antifungal treatment ([Extended Data Fig. 9](#F13){ref-type="fig"}).
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=============

![Left: Table of compound libraries that were screened using a fluorescence polarization assay at the Institute of Chemistry & Cell Biology (ICCB) facility at Harvard Medical School.\
Right: An *S. cerevisiae* viability screen identifies small molecules that preferentially inhibit growth of *S. cerevisiae* in a concentration-dependent manner in the presence of 5 µM ketoconazole (KET). Top hits from the screen are shown; OD~600~ values are the average of values from duplicate plates.](nihms748468f5){#F5}

![(a) 2-dimensional representation of the H-bonding network between the *Cg*Gal11A KIX domain and *iKIX1* based on docking studies.\
(b) Chemical shift perturbations (CSPs) of ILV methyl resonances. Left: ^1^H-^13^C HSQC showing ILV methyl resonances of *Cg*Gal11A KIX domain in presence (brown) and absence (teal) of *Cg*Pdr1 AD (2-fold excess). Right: ^1^H-^13^C HSQC showing ILV methyl resonances of *Cg*Gal11A KIX domain in presence (purple) and in absence (teal) of *iKIX1* (4-fold excess). Three leucines (L19, L23, L51) show significant CSPs in both spectra.\
(c) Sequence alignment of the *C. glabrata* Gal11A and *S. cerevisiae* Gal11/Med15 KIX domains^[@R26]^.](nihms748468f6){#F6}

![(a) *iKIX1* prevents the ketoconazole (KET)-induced recruitment of *Sc*Gal11/Med15/Mediator to the upstream activating sequences (UAS) of the PDRE-regulated promoter *ScSNQ2* and transcriptional upregulation of *ScSNQ2*.\
(b) HA-Pdr1 occupies PDRE-regulated promoters of *ScPDR5* and *ScSNQ2* in the presence of 20 µM *iKIX1* or vehicle (DMSO) control prior to and following ketoconazole (KET) addition.\
(c) 20 µM *iKIX1* inhibits ketoconazole-induced upregulation of *Sc*Pdr1 target genes *ScPDR5* and *ScSNQ2* in the HA-Pdr1 strain. RNA was harvested concurrently with representative chromatin immunoprecipitation experiment shown in panel (b) at t=0 min. (DMSO, 20 µM *iKIX1*) and t=15 min. after ketoconazole induction (DMSO + KET, 20 µM *iKIX1* + KET). Transcripts are normalized to *ScSCR1* and un-induced DMSO control.\
(a--c) Representative experiment from two biological replicates is shown. Error bars represent mean +/− s.d. of technical replicates; \*P\<0.05, \*\*P\<0.01 and \*\*\*P\<0.001 as calculated by two-tailed Student's t-test.\
(d) RNA-Seq analysis of a wild-type *S. cerevisiae* strain (BY4741) pre-treated with *iKIX1* or vehicle alone then induced with ketoconazole (*iKIX1* + KET and KET, respectively) demonstrate a blunted induction of Pdr1 target genes following *iKIX1* pre-treatment. Data represents means of three biological replicates.\
(e) *iKIX1* pre-treatment does not significantly alter the transcript levels of *PDR1* or *GAL11/GAL11A* in *S. cerevisiae* or *C. glabrata* after azole induction. Cells were pre-incubated with vehicle (DMSO) or *iKIX1* and then induced with 40 µM ketoconazole (+KET) for 15 minutes before harvest. Average value of three biological replicates is shown and error bars represent mean +/− standard deviation; \* P\<0.05, \*\* P\<0.001 as compared to DMSO or DMSO+KET control, calculated by two-tailed Student's t-test.](nihms748468f7){#F7}

![With *iKIX1* pre-treatment, *Cg*Pdr1-dependent transcription of (a) *CgCDR1* and (b) *CgYOR1* remains repressed 120 minutes after ketoconazole induction. SFY114 (*PDR1* wild-type) cells were pre-incubated with vehicle (DMSO) or *iKIX1* and then induced with 40 µM ketoconazole (+KET). Transcript levels were assessed by quantitative RT-PCR prior to and for 120 minutes following ketoconazole induction. Transcript levels are normalized to *CgRDN25-1* and un-induced vehicle control (DMSO) at t=0.\
(c) *iKIX1* *t*reatment alone does not have significant effects on *Cg*Pdr1 target gene induction either in the presence of wild-type (SFY114) or gain-of-function mutant *CgPDR1* (amino acid alterations indicated).\
(d) Table of average *CgCDR1* delta Cp values (Cp~*CgCDR1*~ -- Cp~*CgRDN25-1*~) and corresponding standard deviation for quantitative real-time PCR experiments shown in [Figure 3f](#F3){ref-type="fig"} and Extended Data Figure 4c.\
(a--d) For all panels of Extended Data Figure 4, average value of three biological replicates is shown and error bars represent +/− standard deviation; \* P\<0.05, \*\* p \<0.01, and \*\*\* p \<0.005 as compared to vehicle + ketoconazole control. P values calculated using two-tailed Student's t-test.](nihms748468f8){#F8}

![*iKIX1* inhibits efflux of rhodamine 6G in *PDR1* wild-type, *PDR1^L280F^* and *PDR1^Y584C^* strains. Data points indicate mean of three biological replicates and error bars represent mean +/− s.d.](nihms748468f9){#F9}

![(a,b) *iKIX1* increases the sensitivity of *Cg* strains bearing wild-type *CgPDR1* to azole treatment. Two strains bearing wild-type Cg*PDR1* alleles (SFY114, DSY759) were plated at concentrations differing by ten-fold (10×, 1×) on plates containing increasing concentrations of (a) *iKIX1* to 300 µM in the presence or absence of 1 µM ketoconazole (KETO) or (b) *iKIX1* to 250 µM in the presence or absence of 50 µM fluconazole (FLU).\
(c) *iKIX1* and ketoconazole (KET) have additive effects on the growth of a *CgPDR1* wild-type strain.\
(d) *iKIX1* and ketoconazole (KET) synergistically inhibit the growth of the *CgPDR1^L280F^* mutant.\
(c,d) The EUCAST broth microdilution method^[@R27]^ was used to assess the effects of *iKIX1* and ketoconazole combination treatment. Growth, as assessed by OD~540~, was normalized to no drug control. All combination indices (CI) for the *CgPDR1^L280F^* mutant were less than 1, indicating synergy. A representative of three biological replicates is shown and the red line indicates a combination index of 1.](nihms748468f10){#F10}

![Electron-withdrawing groups in the aromatic ring of *iKIX1* complement the basic binding interface of the *Cg*Gal11A KIX domain and thus play a key role in *iKIX1* function.\
A structurally similar *iKIX1* analog (*A2*) lacking electron-withdrawing groups increases the IC~50~ in the FP assay (a) and abolishes activity in the *S. cerevisiae* luciferase reporter assay (b), repression of *CgCDR1* expression (c), and synergistic *C. glabrata* cell growth inhibition with azoles (d).\
Error bars in (b,c) indicate mean +/− s.d. of technical replicates (reads/real-time PCR reactions, respectively). \*\* P\<0.005; statistical differences calculated using two-tailed Student's t-test.\
(e) *iKIX1* inhibits viability of HepG2 cells at concentrations \>50 µM. The mean of 3 biological replicates is shown; error bars represent means +/− s.d.\
(f) *iKIX1* exhibits no effect on transcription of SREBP-target genes in HepG2 cells at concentrations up to 100 µM. Biological duplicates were assessed; representative experiment is shown and error bars represent means +/− s.d. of technical (real-time PCR) replicates.\
(g) Mouse plasma stability of *iKIX1* and mouse and human microsomal stability of *iKIX1*, n=1\
(h) *In vivo* pharmacokinetic parameters of *iKIX1*, n=3 mice per time point.](nihms748468f11){#F11}

![(a) Clinical isolates DSY562/DSY565 (azole sensitive and *PDR1^L280F^* azole-resistant strains, respectively) behave similarly to SFY114/SFY115 (isogenic *PDR1*^+^ and *PDR1^L280F^* strains, shown in [Figure 4d](#F4){ref-type="fig"}) in the mouse infection model. n=10 mice for each treatment condition; \* P\<0.01, \*\* P\<0.005 and \*\*\* P\<0.0001.\
(b) *iKIX1* combination treatment with fluconazole reduces fungal tissue burdens in the spleen or kidney of mice injected with *C. glabrata PDR1^P822L^* (SFY116). n=5 mice for each treatment condition; \*\* P \< 0.01 and \* P \< 0.05.\
(c) 100 mg/kg/day *iKIX1* (high *iKIX1*) treatment of mice infected with SFY93 (*pdr1Δ*) significantly reduces fungal burden in a mouse infection model (CFU/g kidney) alone as compared to SFY114 (*PDR1^+^*) or SFY115 (*PDR1^L280F^*). n=10 mice for each treatment condition; \* P\<0.01, \*\* P\<0.005, \*\*\* P\<0.0001.\
(d) Mice infected with SFY114 (*PDR1^+^*), SFY115 (*PDR1^L280F^*) or SFY93 (*pdr1Δ*) were treated with low (10 mg/kg/day) *iKIX1*, low fluconazole (low FLU; 25 mg/kg/day), fluconazole at 100 mg/kg/day (FLU) or combination with the two. *iKIX1* did not confer additional reductions in CFU/g kidney with SFY93 infection. n=10 mice for each treatment condition. \*\*\* P\<0.0005.\
(e) *iKIX1* and ketoconazole (KETO) reduce adherence of *CgPDR1^L280F^* (SFY116) to CHO-Lec2 cells. Adherence is normalized to SFY114 DMSO control; each column represents the average of 4 biological replicates. \* P\<0.05 as compared to SFY114 DMSO control.\
(f) *iKIX1* (100 mg/kg/day) or fluconazole (FLU) significantly reduces fungal burden in the bladder and kidney in a urinary tract infection model in mice. n=15 mice were infected in each group and points at 0 log~10~ CFU/g organ fell below the detection limit of the method (50 CFU/g organ). \* P\< 0.05, \*\* P\<0.005\
(a--f) Statistical differences were measured using a Mann-Whitney/Wilcoxon rank-sum test as compared to no treatment control; error bars represent means +/− standard deviation.](nihms748468f12){#F12}

![Model of *iKIX1* function as a co-therapeutic in combination with an azole, blocking the azole-induced recruitment of Gal11/Med15-Mediator to Pdr1 target genes upon azole-treatment and preventing the upregulation of Pdr1 target genes, including those which encode drug efflux pumps.](nihms748468f13){#F13}

###### NMR and refinement statistics for *Cg*Gal11A KIX domain

Summary of quality statistics for the ensemble of 10 structures calculated with AMBER explicit water refinement and list of experimental restraints.

                                                                    Protein
  ----------------------------------------------------------------- ---------------
  **NMR distance and dihedral constraints**                         
  Distance constraints                                              
    Total NOE                                                       1718
    Intra-residue                                                   602
    Inter-residue                                                   1116
      Sequential (\|i−j\| = 1)                                      517
      Medium-range (\|i−j\| ≤ 4)                                    488
      Long-range (\|i−j\| ≥ 5)                                      111
    Hydrogen bonds                                                  0
  Total dihedral angel restraints                                   158
    phi                                                             79
    psi                                                             79
  **Structure statistics**                                          
  Violations (mean and s.d.)                                        
    Distance constraints (Å)                                        0.083 ± 0.039
    Dihedral angel constraints (°)                                  2.407 ± 0.357
    Max. dihedral angel violation (°)                               10.267
    Max. distance constraint violation (Å)                          0.248
  Deviations from idealized geometry                                
    Bond lengths (Å)                                                0.013
    Bond angles (°)                                                 1.9
  Average pairwise r.m.s.d.[\*\*](#TFN1){ref-type="table-fn"} (Å)   
    Heavy                                                           1.1
    Backbone                                                        0.7

Pairwise r.m.s.d. was calculated among ordered residues (3--83) of 10 refined structures.
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![Discovery of inhibitors of the *Cg*Gal11A KIX-*Cg*Pdr1AD interaction interface\
(a) Schematic of the screening process.\
(b) *iKIX1* inhibits cell growth in a concentration-dependent manner in the presence of 5 µM ketoconazole (KET); error bars represent means +/− s.d. from duplicate plates.\
(c) *iKIX1* structure.\
(d) FP titration curve showing the interaction of *Cg*Gal11A KIX domain with *Cg*Pdr1 AD30 fitted to a K~d~ of 319.7 nM ± 9.5 nM (left). *iKIX1* competes out *Cg*Pdr1 AD30 with an IC50 of 190.2 µM ± 4.1 µM (right). The measured K~d~ and IC50 values were used to calculate an apparent Ki of 18.1 µM for *iKIX1*. Data represent mean of two replicates and standard error from the fit is shown.](nihms748468f1){#F1}

![Elucidation of the *Cg*Gal11A KIX domain structure; *Cg*Pdr1 AD and *iKIX1* bind to a similar interface on the *Cg*Gal11A KIX domain\
(a) Backbone representation of the 10 lowest energy NMR structures of *Cg*Gal11A KIX domain; backbone RMSD \~ 0.7 Å, left. Overlay of *Cg*Gal11A (purple) and *S. cerevisiae* Gal11/Med15 (blue) KIX domains, with an overall RMSD of 2.0 Å^[@R25]^, right.\
(b) Chemical shift perturbations (CSPs) on the *Cg*Gal11A KIX domain in the presence of *Cg*Pdr1 AD (red) or *iKIX1* (blue). Residues coloured in red or blue indicate a chemical shift perturbation greater than 2 s.d. Residues highlighted in green (L19, L23 and L51) represent significant CSPs in the side-chain methyl groups of an ILV labeled sample.\
(c) The *iKIX1* and *Cg*Pdr1 AD target the hydrophobic groove on the *Cg*Gal11A KIX domain, which is surrounded by a basic patch. Residues H43, K54, K68, K78, R79, F47 and M72 present a positive electrostatic surface enclosing the binding interface.\
(d) *iKIX1* docked to the *Cg*Gal11A KIX domain. *iKIX1* is depicted as red sticks and spheres. Residues that experience significant methyl CSP upon addition of *iKIX1* are depicted as blue sticks.](nihms748468f2){#F2}

![*iKIX1* blocks Gal11/Med15 recruitment and upregulation of Pdr1 target genes\
(a) *iKIX1* inhibits ketoconazole (KET)-induced upregulation of luciferase activity in a dose-responsive manner in a *Sc pdr1Δpdr3Δ* strain containing plasmid-borne *CgPDR1* and 3XPDRE-luciferase. (UT): untreated control; \*\* P\<0.001.\
(b,c) *iKIX1* prevents the ketoconazole (KET)-induced recruitment of Gal11/Med15/Mediator to the upstream activating sequences (UAS) of the PDRE-regulated promoter *ScPDR5* (B), and *ScPDR5* induction (C). Representative experiment from two biological replicates (ChIP DNA and RNA from same experiment) is shown. Error bars indicate s.d. of technical replicates; \*\*\* P\<0.00001, \*\* P\<0.0005, and \* P\<0.01 by two-tailed Student's t-test.\
(d) *iKIX1* inhibits ketoconazole (KET)-induced transcriptional upregulation of *CgCDR1* and *CgCDR2* in a *CgPDR1* wild-type strain (SFY114). \*\* P\<0.005.\
(e) RNA-Seq analysis of a *C. glabrata* SFY114 (*PDR1* wild-type) strain pre-treated with *iKIX1* or vehicle alone then induced with ketoconazole (*iKIX1* + KET and KET, respectively).\
(f) *iKIX1* inhibits xenobiotic-induced *Cg*Pdr1 transcription in *Cg*Pdr1 gain-of-function mutants (amino acid changes indicated). Samples shown were induced with ketoconazole. \* P\<0.05 and \*\* P\<0.01 as compared to DMSO + ketoconazole control.\
(g) *iKIX1* inhibits rhodamine 6G efflux in *C. glabrata* as compared to vehicle control. \* P\<0.05, \*\* P\<0.005 as compared to DMSO + ketoconazole control.\
(a,d,e,f,g) Data represent the means of three biological replicates. Two-tailed student's t-test used to determine P values; error bars represent means +/− standard deviation.](nihms748468f3){#F3}

![*iKIX1* as a co-therapeutic in models of *C. glabrata* disseminated disease\
(a) Schematic showing *Cg*Pdr1 gain-of-function alterations in relation to putative functional domains. DBD: DNA-binding domain, ID: inhibitory domain, MHR: middle homology region, AD: activation domain.\
(b) *iKIX1* restores the efficacy of azoles towards *CgPDR1* gain-of-function mutants. Plates contained increasing concentrations of vehicle control (DMSO) or *iKIX1* to 150 µM in the absence or presence of fluconazole (FLU) or ketoconazole (KET).\
(c) *iKIX1* in combination with fluconazole but not fluconazole alone significantly extended survival of *G. mellonella* larvae injected with *CgPDR1^L280F^* (SFY115, n=9). For SFY114, n=10. \* P\<0.05, \*\*\* P\<0.001 as compared to PBS vehicle control. Statistical differences measured using a log-rank (Mantel-Cox) test.\
(d) *iKIX1* combination treatment with 25 mg/kg fluconazole (low FLU) reduces fungal tissue burden in the kidney or spleen of mice injected with *CgPDR1* wild-type (SFY114); *iKIX1* in combination with 100 mg/kg fluconazole (high FLU) reduces fungal tissue burden in the kidney or spleen of mice injected with *CgPDR1^L280F^* (SFY115). N=5 mice for each treatment condition; \* P\<0.05, \*\* P\< 0.005 and \*\*\* P\< 0.0001 as compared to no treatment. Statistical differences measured using a Wilcoxon rank-sum test; error bars represent means +/− standard deviation.](nihms748468f4){#F4}
